179 related articles for article (PubMed ID: 30760581)
1. DP
Saunders R; Kaul H; Berair R; Gonem S; Singapuri A; Sutcliffe AJ; Chachi L; Biddle MS; Kaur D; Bourne M; Pavord ID; Wardlaw AJ; Siddiqui SH; Kay RA; Brook BS; Smallwood RH; Brightling CE
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760581
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin D
Carstensen S; Gress C; Erpenbeck VJ; Kazani SD; Hohlfeld JM; Sandham DA; Müller M
Respir Res; 2021 Oct; 22(1):262. PubMed ID: 34620168
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology of the prostaglandin D
Brightling C; Kulkarni S; Lambrecht BN; Sandham D; Weiss M; Altman P
Pulm Pharmacol Ther; 2021 Jun; 68():102030. PubMed ID: 33826946
[TBL] [Abstract][Full Text] [Related]
4. Fevipiprant, a DP
Shamri R; Dubois G; Erpenbeck VJ; Mankuta D; Sandham DA; Levi-Schaffer F
Clin Exp Allergy; 2019 Feb; 49(2):255-257. PubMed ID: 30379368
[No Abstract] [Full Text] [Related]
5. The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D
Chen W; Luo J; Ye Y; Hoyle R; Liu W; Borst R; Kazani S; Shikatani EA; Erpenbeck VJ; Pavord ID; Klenerman P; Sandham DA; Xue L
J Immunol; 2021 Jun; 206(11):2714-2724. PubMed ID: 34011519
[TBL] [Abstract][Full Text] [Related]
6. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
7. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse.
Spik I; Brénuchon C; Angéli V; Staumont D; Fleury S; Capron M; Trottein F; Dombrowicz D
J Immunol; 2005 Mar; 174(6):3703-8. PubMed ID: 15749909
[TBL] [Abstract][Full Text] [Related]
8. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma.
Kelly MM; O'Connor TM; Leigh R; Otis J; Gwozd C; Gauvreau GM; Gauldie J; O'Byrne PM
J Allergy Clin Immunol; 2010 Feb; 125(2):349-356.e13. PubMed ID: 19969339
[TBL] [Abstract][Full Text] [Related]
9. The prostaglandin D
Domingo C; Palomares O; Sandham DA; Erpenbeck VJ; Altman P
Respir Res; 2018 Sep; 19(1):189. PubMed ID: 30268119
[TBL] [Abstract][Full Text] [Related]
10. Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.
Issahaku AR; Agoni C; Soremekun OS; Kubi PA; Kumi RO; Olotu FA; Soliman MES
Comb Chem High Throughput Screen; 2019; 22(8):521-533. PubMed ID: 31538888
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.
Uller L; Mathiesen JM; Alenmyr L; Korsgren M; Ulven T; Högberg T; Andersson G; Persson CG; Kostenis E
Respir Res; 2007 Feb; 8(1):16. PubMed ID: 17328802
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Prostaglandin D2 Receptor 2 Antagonism with Fevipiprant for Patients with Asthma: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang D; Guo X; Liu T; Li Y; Du Z; Liu C
Curr Allergy Asthma Rep; 2021 Aug; 21(7):39. PubMed ID: 34387775
[TBL] [Abstract][Full Text] [Related]
13. Investigational prostaglandin D2 receptor antagonists for airway inflammation.
Santini G; Mores N; Malerba M; Mondino C; Macis G; Montuschi P
Expert Opin Investig Drugs; 2016 Jun; 25(6):639-52. PubMed ID: 27094922
[TBL] [Abstract][Full Text] [Related]
14. Fevipiprant, an oral prostaglandin DP
Bateman ED; Guerreros AG; Brockhaus F; Holzhauer B; Pethe A; Kay RA; Townley RG
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28838980
[TBL] [Abstract][Full Text] [Related]
15. Regulation of human airway smooth muscle cell migration and relevance to asthma.
Salter B; Pray C; Radford K; Martin JG; Nair P
Respir Res; 2017 Aug; 18(1):156. PubMed ID: 28814293
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PGD
Kupczyk M; Kuna P
Drugs; 2017 Aug; 77(12):1281-1294. PubMed ID: 28612233
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin D
Marone G; Galdiero MR; Pecoraro A; Pucino V; Criscuolo G; Triassi M; Varricchi G
Expert Opin Investig Drugs; 2019 Jan; 28(1):73-84. PubMed ID: 30513028
[TBL] [Abstract][Full Text] [Related]
18. The relationship between eosinophilia and airway remodelling in mild asthma.
Wilson SJ; Rigden HM; Ward JA; Laviolette M; Jarjour NN; Djukanović R
Clin Exp Allergy; 2013 Dec; 43(12):1342-50. PubMed ID: 24261944
[TBL] [Abstract][Full Text] [Related]
19. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
[TBL] [Abstract][Full Text] [Related]
20. PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-
Werder RB; Lynch JP; Simpson JC; Zhang V; Hodge NH; Poh M; Forbes-Blom E; Kulis C; Smythe ML; Upham JW; Spann K; Everard ML; Phipps S
Sci Transl Med; 2018 May; 10(440):. PubMed ID: 29743346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
